Actelion Rises to 2-Year High as Company May Raise Forecast

Actelion Ltd., the Swiss drugmaker that gets most of its sales from one drug, rose to the highest in more than two years after saying it may raise its full-year forecast and reporting first-quarter profit that beat estimates.

http://washpost.bloomberg.com/Story?docId=1376-MLAZE86JIJVS01-0NNCJ8V97UKHJ0I0N153N8S9NF